Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive human cancers, and novel treatment modalities are required. We investigated the therapeutic potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) in combination with the proteasome inhibitor bort...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2010-06, Vol.9 (6), p.1842-1851
Hauptverfasser:	Seki, Naoko, Toh, Uhi, Sayers, Thomas J, Fujii, Teruhiko, Miyagi, Motoshi, Akagi, Yoshito, Kusukawa, Jingo, Kage, Masayoshi, Shirouzu, Kazuo, Yamana, Hideaki
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis - drug effects Boronic Acids - pharmacology Bortezomib Carcinoma, Squamous Cell - enzymology Carcinoma, Squamous Cell - pathology CASP8 and FADD-Like Apoptosis Regulating Protein - metabolism Caspases - metabolism Cell Line, Tumor Death Domain Receptor Signaling Adaptor Proteins - metabolism Drug Resistance, Neoplasm - drug effects Drug Screening Assays, Antitumor Drug Synergism Esophageal Neoplasms - enzymology Esophageal Neoplasms - pathology Humans Pyrazines - pharmacology Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism Signal Transduction - drug effects TNF-Related Apoptosis-Inducing Ligand - pharmacology Up-Regulation - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!